Please login to the form below

Not currently logged in
Email:
Password:

MET inhibitor

This page shows the latest MET inhibitor news and features for those working in and with pharma, biotech and healthcare.

Keytruda improves survival in first-line oesophageal cancer

Keytruda improves survival in first-line oesophageal cancer

The PD-L1 inhibitor met both primary endpoints of overall survival (OS) and progression-free survival (PFS) in the study, and improved outcomes compared to the current standard of care. ... treatment. In the phase 3 ATTRACTION-3 trial, which evaluated

Latest news

  • Merck gets first approval for MET inhibitor tepotinib in Japan Merck gets first approval for MET inhibitor tepotinib in Japan

    First worldwide approval for MET inhibitor. Japan’s medicines regulator has approved Merck KGaA’s oral MET inhibitor tepotinib for non-small cell lung cancer with MET exon 14 (METex14) mutations, ... The Japanese approval is the first worldwide for

  • Incyte’s JAK inhibitor cream clears second eczema trial Incyte’s JAK inhibitor cream clears second eczema trial

    The reformulation could open up a new and very large treatment category for the drug, as well as new territory for the JAK inhibitor class. ... The oral JAK inhibitor market is split between drugs used to treat cancer, like Jakafi, and those used for

  • Novartis pulls ahead of Merck in MET-positive lung cancer race Novartis pulls ahead of Merck in MET-positive lung cancer race

    FDA starts priority review of Swiss pharma's MET inhibitor. Novartis’ MET inhibitor capmatinib could be approved for marketing in the US within six months for a rare form of ... The start of the review puts Novartis in a position to bring a drug for MET

  • Exelixis bounces back with new prostate cancer data Exelixis bounces back with new prostate cancer data

    It seems like that sacrifice was worth it, with cabozantinib in combination with PD-1 inhibitor Tecentriq (atezolizumab) hitting the primary endpoint of an improved objective response rate. ... Cabozantinib, a c-MET and VEGFR2 inhibitor, is already

  • Merck buys ArQule for $2.7bn in another cancer bolt-on deal Merck buys ArQule for $2.7bn in another cancer bolt-on deal

    The deal – due to close in the first quarter of 2020 – will give Merck ownership of ARQ 531, a BTK inhibitor that has just reported more encouraging data in B-cell ... trials, with recent fails including c-MET inhibitor tivantinib.

More from news
Approximately 2 fully matching, plus 31 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much
Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website
You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...

Infographics